SOUTH SAN FRANCISCO, Calif. , Sept. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…
The CD19/CD70 Dual CAR is Specifically Designed to Address Both the B-cell and T-cell Dysfunction Implicated in Autoimmune Diseases ALLO-329, is an Investigational Product Built on a New Gene Editing…
SOUTH SAN FRANCISCO, Calif. , Aug. 08, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…
Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation in Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Initiated in June 2024 Patient Screening for Minimal Residual Disease (MRD) and Enrollment Proceeding as…
Conference Call and Webcast Scheduled for August 7, 2024 at 2:00 p.m. PT / 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. , July 31, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics…
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute ; Astera Cancer Care, Part of the OneOncology Network; and…
ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure Rates First Prospective Trial to Incorporate the Foresight Diagnostics’s Investigational…
SOUTH SAN FRANCISCO, Calif. , May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…
SOUTH SAN FRANCISCO, Calif. , May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…
Cemacabtagene Ansegedleucel (Cema-Cel) Expanded CD19 Oncology Rights to Include all EU Member States and the United Kingdom , Reinforcing Company’s Conviction in the Unique Opportunity in Large B Cell Lymphoma…